Gerardo Rosati | Breast Cancer | Best Researcher Award

Dr. Gerardo Rosati | Breast Cancer | Best Researcher Award

Azienda Ospedaliera San Carlo di Potenza | Italy

Dr. Gerardo Rosati is a distinguished Italian medical oncologist whose career reflects over three decades of sustained clinical practice, research leadership, and commitment to advancing evidence-based cancer care. Laureato con lode all’Università “Federico II” di Napoli e successivamente specializzato in Oncologia presso la Seconda Università di Napoli, ha sviluppato precocemente un interesse scientifico per i markers tumorali e per l’innovazione terapeutica nei tumori solidi. La sua formazione è stata arricchita da numerose borse di studio FIRC, ESO e Fondazione Lina Belli, che gli hanno consentito di partecipare a corsi avanzati internazionali su colon-retto, neuro-oncologia, recidive ginecologiche, terapia antalgica e strategie emergenti in oncologia medica. Dal 1998 opera stabilmente presso l’U.O. di Oncologia Medica dell’Azienda Ospedaliera “S. Carlo” di Potenza, dove ha assunto ruoli via via più qualificati fino alla responsabilità del coordinamento dell’attività di ricerca clinica. La sua attività come sperimentatore in oltre cento studi clinici di fase I–III e in numerosi progetti osservazionali riguarda chemioterapie innovative, farmaci biologici, anti-EGFR, anti-angiogenici, immunoterapia, tossicità correlate ai trattamenti e biomarcatori predittivi. Ha inoltre svolto un’intensa attività di revisione scientifica per riviste internazionali e per enti accademici e sanitari nazionali, contribuendo al miglioramento della qualità metodologica della ricerca oncologica. Membro attivo di AIOM, ESMO ed ESO College, promuove l’integrazione tra clinica, ricerca e formazione, con un impatto significativo sui percorsi assistenziali nei tumori gastrointestinali e in altre neoplasie solide. His academic influence is reflected in 2,813 citations, 123 documents, and an h-index of 27, underscoring his meaningful contributions to contemporary clinical oncology.

Profiles: Scopus | ORCID

Featured Publications

1. Rosati, G., De Stefano, A., Restivo, A., Fanotto, V., Cicero, G., Colombo, A., Dell’Aquila, E., Parisi, A., Ortolani, S., Lutrino, S. E., Carlomagno, C., Dapoto, F., Reggiardo, G., Tonetto, F., Ravo, V., Aprile, G., Bilancia, D., Avallone, A., Romano, C., Argiolas, V., & Giovinazzo, G. (2026). Short-Course Radiotherapy for Older Patients with Locally Advanced Rectal Cancer and Unfit for Chemotherapy: The SOFT Study. Radiotherapy and Oncology.

2. Rosati, G., Piccirillo, M. C., Nasti, G., De Stefano, A., Carlomagno, C., Romano, C., Cassata, A., Silvestro, L., Nappi, A., Perrone, F., Budillon, A., & Avallone, A. (2025). A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study. Drugs & Aging, 1–10.

3. Avallone, A., Giuliani, F., De Stefano, A., Santabarbara, G., Nasti, G., Montesarchio, V., Rosati, G., Cassata, A., Leo, S., Romano, C., Tamburini, E., Silvestro, L., Lotesoriere, C., Nappi, A., Santini, D., Petrillo, A., Colombo, A., Febbraro, A., Leone, A., Mannavola, F., & Laterza, M. M. (2024). Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial. Journal of Clinical Oncology, 43(7), 829–839.

4. Montrone, M., Rosati, G., Longo, V., Catino, A., Massafra, R., Nardone, A., Pesola, F., Montagna, E. S., Marech, I., & Pizzutilo, P. (2023). Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. Journal of Clinical Medicine, 12(5), 1833.

5. Rosati, G., Montrone, M., Pacilio, C., Colombo, A., Cicero, G., Paragliola, F., Vaia, A., Annunziata, L., & Bilancia, D. (2022). An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer. Journal of Clinical Medicine, 11(23), 7108.

Aminah Alotaibi | Breast Cancer | Best Researcher Award

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.